CDK4 and breast carcinoma: We experienced a unique case of postmenopausal HR+HER2− breast cancer with multiple lung and liver metastases after local recurrence, which achieved CR by switching from palbociclib to abemaciclib as a CDK4/6 inhibitor, and subsequently remained disease free.